AbbVie, Jacobio to collaborate on SHP2 inhibitors

By The Science Advisory Board staff writers

June 1, 2020 -- AbbVie and Jacobio Pharmaceuticals announced they are partnering to develop and market SHP2 inhibitors, which target a node in cancer and immune cells.

Inhibition of the SHP2 protein reduces cancer cell growth and prompts antitumor immune response, according to the firms. Jacobio has developed early-clinical-stage oral small molecules called JAB-3068 and JAB-3312 that inhibit SHP2 activity.

Under terms of the deal, Jacobio will grant AbbVie exclusive license to its SHP2 portfolio. It will continue to conduct clinical trials, for which AbbVie will cover expenses.


Copyright © 2020 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?